Lung cancer is the leading cause of cancer mortality worldwide due to limited therapeutic options and low five-year survival rate (15%). Chemotherapy is the standard method for treating advanced or recurrent lung cancer patients, although other methods such as immunotherapy are also available for a small portion of patients. Nevertheless, challenges remain for chemotherapy, including severe side effects and the development of resistance to chemotherapy (chemoresistance). Chemoresistance results from intrinsic and/or acquired drug resistance, the latter of which causes the majority of chemotherapy failures during the cancer invasion/metastasis stages. Chemoresistance enables cancer cells to evade cell death from chemotherapeutic drugs, leading to relapse and/or metastasis to distal organs. Thus, it is important to understand the molecular mechanisms of chemoresistance and discover counteracting approaches for treating these cancer patients.
One emerging approach is personalized medicine. Personalized medicine is distinct from the traditional ‘one-size-fits-all’ medicine in that it is based on the unique molecular and genetic profile of an individual. Individual characterization relies on comprehensive analyses of genomics, proteomics, metabolomics, epigenetics, as well as environmental factors. In addition, bioinformatics can be utilized to evaluate the relationship between those factors and the disease status.
We would like to acknowledge and credit Dr. Chunya Lu has acted as coordinator and have contributed to the preparation of the proposal for this Research Topic.
We welcome Original Research, Reviews, Mini Review, Perspective, Methods, Protocols, Case Report, Clinical Trial and Opinion on the following topics (but not limited to):
• molecular mechanisms of lung cancer chemoresistance
• personalized medicine for lung cancer patients
• new prognosis/therapeutic biomarkers, targets, and strategies for lung cancer patients
Lung cancer is the leading cause of cancer mortality worldwide due to limited therapeutic options and low five-year survival rate (15%). Chemotherapy is the standard method for treating advanced or recurrent lung cancer patients, although other methods such as immunotherapy are also available for a small portion of patients. Nevertheless, challenges remain for chemotherapy, including severe side effects and the development of resistance to chemotherapy (chemoresistance). Chemoresistance results from intrinsic and/or acquired drug resistance, the latter of which causes the majority of chemotherapy failures during the cancer invasion/metastasis stages. Chemoresistance enables cancer cells to evade cell death from chemotherapeutic drugs, leading to relapse and/or metastasis to distal organs. Thus, it is important to understand the molecular mechanisms of chemoresistance and discover counteracting approaches for treating these cancer patients.
One emerging approach is personalized medicine. Personalized medicine is distinct from the traditional ‘one-size-fits-all’ medicine in that it is based on the unique molecular and genetic profile of an individual. Individual characterization relies on comprehensive analyses of genomics, proteomics, metabolomics, epigenetics, as well as environmental factors. In addition, bioinformatics can be utilized to evaluate the relationship between those factors and the disease status.
We would like to acknowledge and credit Dr. Chunya Lu has acted as coordinator and have contributed to the preparation of the proposal for this Research Topic.
We welcome Original Research, Reviews, Mini Review, Perspective, Methods, Protocols, Case Report, Clinical Trial and Opinion on the following topics (but not limited to):
• molecular mechanisms of lung cancer chemoresistance
• personalized medicine for lung cancer patients
• new prognosis/therapeutic biomarkers, targets, and strategies for lung cancer patients
